Thermo Fisher Scientific Catumaxomab Recombinant Human Monoclonal Antibody

Applications

Tested Dilution

Publications

ELISA (ELISA)

Assay-dependent

-

Product Specifications

Host/Isotype

Human / IgG2a, kappa/IG2b, lambda

Class

Recombinant Monoclonal

Type

Antibody

Immunogen

Human CD3E/EpCAM

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Wet ice

RRID

AB_2910966

Product Specific Information

Endotoxin level < 0.01EU/µg by LAL method

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Target Information

Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites3. Its market authorization was withdrawn in the EU in June 2017 at the manufacturers request due to the companys insolvency. Catumaxumab was approved for market in Canada in May 2012 for the same conditionLabel. It is currently available under the brand name Removab.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.